A recent failed HIV prevention drug trial in Africa has raised concerns over the ethical design and implementation of research involving payment to participants in poor countries.
According to the New York Times: “The trial — known by the acronym Voice, for Vaginal and Oral Interventions to Control the Epidemic — was abruptly halted by independent safety monitors because it was not working: Women who were given pills or vaginal gels containing anti-H.I.V. drugs were becoming infected at roughly the same rate as women who were given placebos.”
Fordham University Center for Ethics Education Director Dr. Celia B. Fisher is also the director of the HIV and Drug Abuse Research Ethics Training Institute (RETI) — a program funded by a grant from the National Institute on Drug Abuse (# 1R25DA031608-01), for which she also serves as the principal investigator.
“Be wary of blaming payment for research participation for inadequate research methods and participant consultation,” Fisher, an internationally renowned expert in research ethics and health disparities, advised.
“The Voice investigators were surprised that so many women refused to take the HIV preventive medications, focusing on payments of $10 as a form of coercion that led to continued but deceptive participation,” she continued.
“Engaging participants in respectful, culturally sensitive and continuous discussion on their hopes and fears regarding trial medications and developing timely blood monitoring procedures would have prevented the study’s failure and prevented the unfortunate delay in provision of adequate HIV preventive treatments that this population deserves,” Fisher concluded.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.